Supplemental Table 1

*Cross-Lagged Model Autoregression Pathways*

|  |  |  |  |
| --- | --- | --- | --- |
| Variable |  β |  S.E. | *p* |
| Re-experiencing | 0.461 | 0.029 | <.001 |
| Avoidance | 0.433 | 0.040 | <.001 |
| Emotional numbing | 0.378 | 0.041 | <.001 |
| Dysphoric arousal | 0.308 | 0.029 | <.001 |
| Anxious arousal | 0.484 | 0.037 | <.001 |
| Conflict-related distress | 0.251 | 0.037 | <.001 |
| Days of past-month contact | 0.348 | 0.026 | <.001 |

Supplemental Table 2

*Associations Among Covariates, PTSD Symptoms, and Social Connectedness at Baseline*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  |  Re-experiencing  | Avoidance | Emotional Numbing | Dysphoric Arousal | Anxious Arousal |
| Baseline Variable | β | S.E. | *p* | β | S.E. | *p* | β | S.E. | *p* | β | S.E. | *p* | β | S.E. | *p* |
| Age | - | - | - | -0.06 | 0.03 | 0.02 | -0.11 | 0.03 | <.001 | -0.24 | 0.03 | <.001 | - | - | - |
| Combat status | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Marriage status | - | - | - | - | - | - | - | - | - | 0.08 | 0.02 | 0.001 | - | - | - |
|  | Conflict-related distress | Days of past-month contact |  |  |  |  |  |  |  |  |
|  | β | S.E. | *p* | β | S.E. | *p* |  |  |  |  |  |  |  |  |  |
| Age | -0.29 | 0.02 | <.001 | - | - | - |  |  |  |  |  |  |  |  |  |
| Combat status | - | - | - | -0.07 | 0.03 | 0.006 |  |  |  |  |  |  |  |  |  |
| Marital status | 0.17 | 0.02 | <.001 | 0.21 | 0.03 | <.001 |   |   |   |   |   |   |   |   |   |

Supplemental Table 3

*Associations Among Covariates, PTSD Symptoms, and Social Connectedness at Follow-Up*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  |  Re-experiencing  | Avoidance | Emotional Numbing | Dysphoric Arousal | Anxious Arousal |
| Baseline Variable | β | S.E. | *p* | β | S.E. | *p* | β | S.E. | *p* | β | S.E. | *p* | β | S.E. | *p* |
| Age | - | - | - | - | - | - | 0.07 | 0.02 | < .001 | - | - | - | - | - | - |
| Gender | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Combat status | - | - | - | - | - | - | 0.04 | 0.02 | 0.01 | 0.06 | 0.02 | 0.001 | 0.05 | 0.02 | <.01 |
| Marital status | - | - | - | - | - | - | 0.04 | 0.02 | 0.04 | 0.04 | 0.02 | 0.04 | - | - | - |
| Substance use disorder | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Length of stay  | -0.04 | 0.02 | 0.02 | - | - | - | -0.046 | 0.018 | 0.01 | - | - | - | -0.06 | 0.02 | <.01 |
| Treatment completion | -0.05 | 0.02 | 0.01 | -0.05 | 0.02 | 0.03 | -0.05 | 0.02 | 0.02 | -0.07 | 0.02 | <.001 | - | - | - |
|  | Conflict-related distress | Days of past-month contact |  |  |  |  |  |  |  |  |
|  | β | S.E. | *p* | β | S.E. | *p* |  |  |  |  |  |  |  |  |  |
| Age | - | - | - | - | - | - |  |  |  |  |  |  |  |  |  |
| Gender | 0.06 | 0.02 | 0.01 | - | - | - |  |  |  |  |  |  |  |  |  |
| Combat status | - | - | - | - | - | - |   |   |   |   |   |   |   |   |   |
| Marital status | 0.05 | 0.02 | 0.02 | 0.09 | 0.03 | <.001 |  |  |  |  |  |  |  |  |  |
| Substance use disorder | - | - | - | 0.09 | 0.02 | <.001 |  |  |  |  |  |  |  |  |  |
| Length of stay  | - | - | - | 0.09 | 0.03 | <.001 |  |  |  |  |  |  |  |  |  |
| Treatment completion | - | - | - | - | - | - |  |  |  |  |  |  |  |  |  |

Supplemental Table 4

*Cross-lagged Item Analysis Path Model: Cross-Lagged Associations Between Individual PTSD Symptoms at Baseline and Social Connectedness at Follow-up*

|  |  |  |
| --- | --- | --- |
| Variable (Baseline) | Conflict-Related Distress at Follow-up | Days of Past-month Contact at Follow-up |
|  | *B* | *S.E.* | *p* | *B* | *S.E.* | *p* |
| Intercept | 0.85 | 0.27 | 0.002 | 1.48 | 0.29 | <.001 |
| PCL-1  | -0.01 | 0.03 | 0.87 | 0.04 | 0.04 | 0.26 |
| PCL-2  | -0.04 | 0.03 | 0.17 | 0.00 | 0.03 | 0.92 |
| PCL-3  | 0.00 | 0.03 | 0.92 | -0.02 | 0.03 | 0.64 |
| PCL-4  | 0.04 | 0.03 | 0.17 | 0.06 | 0.03 | 0.10 |
| PCL-5  | -0.01 | 0.03 | 0.71 | 0.00 | 0.03 | 0.93 |
| PCL-6  | -0.02 | 0.03 | 0.55 | 0.00 | 0.03 | 0.89 |
| PCL-7  | 0.01 | 0.03 | 0.71 | -0.05 | 0.03 | 0.14 |
| PCL-8  | -0.01 | 0.02 | 0.72 | 0.04 | 0.03 | 0.13 |
| PCL-9  | 0.04 | 0.03 | 0.25 | 0.01 | 0.03 | 0.63 |
| PCL-10  | -0.02 | 0.03 | 0.50 | -0.05 | 0.03 | 0.10 |
| PCL-11  | 0.06 | 0.03 | 0.03 | -0.01 | 0.03 | 0.66 |
| PCL-12  | 0.01 | 0.03 | 0.62 | -0.03 | 0.03 | 0.27 |
| PCL-13  | 0.02 | 0.03 | 0.46 | -0.02 | 0.03 | 0.51 |
| PCL-14  | 0.08 | 0.03 | 0.01\* | -0.01 | 0.03 | 0.65 |
| PCL-15  | 0.00 | 0.03 | 0.90 | 0.07 | 0.03 | 0.02 |
| PCL-16  | -0.02 | 0.03 | 0.61 | -0.02 | 0.03 | 0.48 |
| PCL-17  | -0.02 | 0.03 | 0.62 | 0.01 | 0.03 | 0.73 |

*Note:* Models include all covariates (age, sex, combat status, marital status, SUD, treatment site, treatment length, and treatment completion).

Supplemental Table 5

*Cross-lagged Item Analysis Path Model: Associations Between Baseline Social Connectedness and Follow-Up Individual PTSD Symptoms*

|  |  |  |  |
| --- | --- | --- | --- |
| Variable | *B* | *S.E.* | *p* |
| PCL-1 at follow-up |  |  |  |
|  Intercept | 2.21 | 0.26 | <.001 |
|  Baseline conflict-related distress | 0.14 | 0.03 | 0.60 |
|  Baseline days of contact | -0.01 | 0.02 | 0.19 |
| PCL-2 at follow-up |  |  |  |
|  Intercept | 2.05 | 0.24 | <.001 |
|  Baseline conflict-related distress | 0.11 | 0.03 | <.001\* |
|  Baseline days of contact | -0.04 | 0.02 | 0.12 |
| PCL-3 at follow-up |  |  |  |
|  Intercept | 1.71 | 0.24 | <.001 |
|  Baseline conflict-related distress | 0.11 | 0.03 | <.001\* |
|  Baseline days of contact | -0.07 | 0.02 | 0.002\* |
| PCL-4 at follow-up |  |  |  |
|  Intercept | 2.28 | 0.25 | <.001 |
|  Baseline conflict-related distress | 0.15 | 0.03 | <.001\* |
|  Baseline days of contact | -0.03 | 0.02 | 0.15 |
| PCL-5 at follow-up |  |  |  |
|  Intercept | 2.17 | 0.24 | <.001 |
|  Baseline conflict-related distress | 0.13 | 0.03 | <.001\* |
|  Baseline days of contact | -0.05 | 0.02 | 0.06 |
| PCL-6 at follow-up |  |  |  |
|  Intercept | 2.56 | 0.26 | <.001 |
|  Baseline conflict-related distress | 0.13 | 0.03 | <.001\* |
|  Baseline days of contact | -0.03 | 0.03 | 0.25 |
| PCL-7 at follow-up |  |  |  |
|  Intercept | 2.19 | 0.25 | <.001 |
|  Baseline conflict-related distress | 0.09 | 0.03 | <.001\* |
|  Baseline days of contact | -0.08 | 0.02 | 0.001\* |
| PCL-8 at follow-up |  |  |  |
|  Intercept | 0.98 | 0.21 | <.001 |
|  Baseline conflict-related distress | 0.02 | 0.03 | 0.51 |
|  Baseline days of contact | -0.002 | 0.02 | 0.95 |
| PCL-9 at follow-up |  |  |  |
|  Intercept | 1.53 | 0.25 | <.001 |
|  Baseline conflict-related distress | 0.14 | 0.03 | <.001\* |
|  Baseline days of contact | -0.08 | 0.02 | .001\* |
| PCL-10 at follow-up |  |  |  |
|  Intercept | 1.89 | 0.26 | <.001 |
|  Baseline conflict-related distress | 0.13 | 0.03 | <.001\* |
|  Baseline days of contact | -0.09 | 0.02 | <.001\* |
| PCL-11 at follow-up |  |  |  |
|  Intercept | 1.94 | 0.25 | <.001 |
|  Baseline conflict-related distress | 0.10 | 0.03 | <.001\* |
|  Baseline days of contact | -0.10 | 0.02 | <.001\* |
| PCL-12 at follow-up |  |  |  |
|  Intercept | 0.93 | 0.23 | <.001 |
|  Baseline conflict-related distress | 0.08 | 0.03 | 0.001\* |
|  Baseline days of contact | -0.04 | 0.02 | 0.13 |
| PCL-13 at follow-up |  |  |  |
|  Intercept | 2.21 | 0.26 | <.001 |
|  Baseline conflict-related distress | 0.04 | 0.03 | 0.14 |
|  Baseline days of contact | -0.002 | 0.02 | 0.95 |
| PCL-14 at follow-up |  |  |  |
|  Intercept | 1.93 | 0.24 | <.001 |
|  Baseline conflict-related distress | 0.10 | 0.03 | <.001\* |
|  Baseline days of contact | -0.03 | 0.02 | 0.17 |
| PCL-15 at follow-up |  |  |  |
|  Intercept | 1.56 | 0.24 | <.001 |
|  Baseline conflict-related distress | 0.10 | 0.03 | <.001\* |
|  Baseline days of contact | 0.01 | 0.02 | 0.68 |
| PCL-16 at follow-up |  |  |  |
|  Intercept | 1.71 | 0.25 | <.001 |
|  Baseline conflict-related distress | 0.12 | 0.03 | <.001\* |
|  Baseline days of contact | -0.01 | 0.02 | 0.69 |
| PCL-17 at follow-up |  |  |  |
|  Intercept | 1.85 | 0.23 | <.001 |
|  Baseline conflict-related distress | 0.08 | 0.03 | 0.001\* |
|  Baseline days of contact | -0.03 | 0.02 | 0.17 |

*Note:* Models include all covariates (age, sex, combat status, marital status, SUD, treatment site, treatment length, and treatment completion).